NCT03906617PHASE4Recruiting
Bupivacaine/Epinephrine +Dexamethasone vs. Liposomal Bupivacaine
The Cooper Health System
Start Date
4/10/2019
Completion Date
6/10/2022
Summary
This study will assess analgesia after robotic lung surgery. Subjects will be randomized to receive wound infiltration and intercostal nerve block with either liposomal bupivacaine or bupivacaine/epinephrine + dexamethasone. Liposomal bupivacaine is a newer local anesthetic product and has not been compared to a combination of bupivacaine/epinephrine + dexamethasone in the context of pain control after robotic lung surgery.
Eligibility Criteria
Age Range: 18 years to 90 years
Inclusion Criteria:
* undergoing robotic wedge resection or lobectomy for lung mass(es)
Exclusion Criteria:
* emergency case
* history of opiate abuse
* chronic pain syndrome
* intravenous drug use
* chronic use of oral steroids
* pregnancy
* imprisonment
* body weight lower than 70 kg
* liver failure
* uninsured patients
* non-verbal patients or patients who are unable to rate their pain on a visual analogue pain scale
* history of allergic reaction to any of the drugs used in the study: bupivacaine, liposomal bupivacaine, dexamethasone
Interventions
DRUG
Intercostal nerve block and wound infiltration with liposomal bupivacaine
DRUG
Intercostal nerve block and wound infiltration with bupivacaine/epinephrine + dexamethasone
Conditions
Robotic Lung Surgery
Locations
Cooper University Hospital
Camden, New Jersey 08103
United States